Literature DB >> 8462799

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.

C Pothoulakis1, C P Kelly, M A Joshi, N Gao, C J O'Keane, I Castagliuolo, J T Lamont.   

Abstract

BACKGROUND: Saccharomyces boulardii is a nonpathogenic yeast used for the prevention and treatment of Clostridium difficile-associated diarrhea and colitis. However, the mechanism by which S. boulardii exerts its protective effects remains unclear.
METHODS: The binding of [3H]toxin A to its brush border receptor preincubated with S. boulardii-cultured suspension or filtered conditioned medium was measured in vitro. The effect of toxin A on secretion, epithelial permeability, and morphology in rat ileal loops in vivo was also examined in rats pretreated with S. boulardii.
RESULTS: S. boulardii reduced [3H]toxin A-receptor binding in a dose-dependent fashion. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of ileal brush border exposed to S. boulardii-conditioned medium revealed a diminution of all brush border proteins. Treatment of rats with S. boulardii suspension reduced fluid secretion and mannitol permeability caused by toxin A.
CONCLUSIONS: S. boulardii may reduce some of the enterotoxic effects of toxin A by inhibiting toxin A-receptor binding. This effect appears to be manifested by a secreted product of the yeast, possibly a protease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462799     DOI: 10.1016/0016-5085(93)90280-p

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

1.  Bacteriological evaluation of dog and cat diets that claim to contain probiotics.

Authors:  J Scott Weese; Luis Arroyo
Journal:  Can Vet J       Date:  2003-03       Impact factor: 1.008

Review 2.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 3.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

4.  Coming full circle: From antibiotics to probiotics and prebiotics.

Authors:  John M Conly; Lynn B Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-05       Impact factor: 2.471

5.  Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.

Authors:  I Castagliuolo; M F Riegler; L Valenick; J T LaMont; C Pothoulakis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae.

Authors:  R L Brandão; I M Castro; E A Bambirra; S C Amaral; L G Fietto; M J Tropia; M J Neves; R G Dos Santos; N C Gomes; J R Nicoli
Journal:  Appl Environ Microbiol       Date:  1998-02       Impact factor: 4.792

7.  Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection.

Authors:  Flaviano S Martins; Guillaume Dalmasso; Rosa M E Arantes; Anne Doye; Emmanuel Lemichez; Patricia Lagadec; Veronique Imbert; Jean-François Peyron; Patrick Rampal; Jacques R Nicoli; Dorota Czerucka
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

8.  CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin.

Authors:  C Pothoulakis; I Castagliuolo; J T LaMont; A Jaffer; J C O'Keane; R M Snider; S E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

9.  Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.

Authors:  Fariborz Mansour-Ghanaei; Najaf Dehbashi; Kamyar Yazdanparast; Afshin Shafaghi
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Probiotics affect virulence-related gene expression in Escherichia coli O157:H7.

Authors:  Maira Jessica Medellin-Peña; Haifeng Wang; Roger Johnson; Sanjeev Anand; Mansel W Griffiths
Journal:  Appl Environ Microbiol       Date:  2007-05-11       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.